Pipeline
Developing oral exosome therapies for life-threatening inflammatory diseases and targeted delivery of biologics to intestinal tissue.
Our Candidates
Our Candidates
Pioneering Breakthroughs
Pioneering Breakthroughs
Our BEX™ platform is designed for scalable, safe, and effective delivery of bioactive molecules to intestinal tissues with minimal systemic exposure—starting in neonatal care and extending to chronic inflammatory disease and cancer.
Our BEX™ platform is designed for scalable, safe, and effective delivery of bioactive molecules to intestinal tissues with minimal systemic exposure—starting in neonatal care and extending to chronic inflammatory disease and cancer.
BEX-114
NEC prevention (Lead Program)
Lead Optimization
Next Stage:
IND-Enabling
BEX-114
NEC prevention (Lead Program)
Lead Optimization
Next Stage:
IND-Enabling
BEX-114
NEC prevention (Lead Program)
Lead Optimization
Next Stage:
IND-Enabling
BEX-114
Mild-moderate UC
Lead Optimization
Next Stage:
IND-Enabling
BEX-114
Mild-moderate UC
Lead Optimization
Next Stage:
IND-Enabling
BEX-114
Mild-moderate UC
Lead Optimization
Next Stage:
IND-Enabling
BEX-214
Adult inflammatory bowel diseases
Discovery
Next Stage:
Lead Optimization
BEX-214
Adult inflammatory bowel diseases
Discovery
Next Stage:
Lead Optimization
BEX-214
Adult inflammatory bowel diseases
Discovery
Next Stage:
Lead Optimization
Expora Overview
Expora is advancing a pipeline of microbiome-derived extracellular vesicle (exosome) therapeutics designed to treat and prevent inflammatory diseases of the intestines. Our lead program targets necrotizing enterocolitis (NEC), a rare and often fatal disease in preterm infants, with additional programs underway in adult ulcerative colitis (UC) and broader inflammatory bowel disease (IBD). All candidates utilize a proprietary platform that isolates therapeutic exosomes from probiotic lactic acid bacteria—organisms naturally found in breast milk and the healthy infant and adult microbiome.
Additional partnered opportunities are available in immuno-oncology and neurologic diseases.
Expora Overview
Expora is advancing a pipeline of microbiome-derived extracellular vesicle (exosome) therapeutics designed to treat and prevent inflammatory diseases of the intestines. Our lead program targets necrotizing enterocolitis (NEC), a rare and often fatal disease in preterm infants, with additional programs underway in adult ulcerative colitis (UC) and broader inflammatory bowel disease (IBD). All candidates utilize a proprietary platform that isolates therapeutic exosomes from probiotic lactic acid bacteria—organisms naturally found in breast milk and the healthy infant and adult microbiome.
Additional partnered opportunities are available in immuno-oncology and neurologic diseases.